Strengthens Sun Pharma's strategic position in Global opiates market
Sun Pharmaceutical Industries announced that it has begun the integration of its Opiates business in Australia following the successful completion of this acquisition from GSK (announced in March 2015). This acquisition fortifies Sun Pharma's global position with two Opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialized team to drive business growth.
The Opiates acquisition allows Sun Pharma to:
Significantly expands its narcotics raw material (NRM) market share.
Enhance Opiate Alkaloids portfolio and depth in Global opiates market.
Strengthen its strategic position in the global Opiates business.
Powered by Capital Market - Live News
